Top Markets
Coin of the day
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Rang in aandelen #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Aandeelprijs
$99.16
Laatst gesynchroniseerd: 2026-08-27
Marktkapitalisatie
$1.72B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
2.52%
Land
ES
Handel Pharma Mar, S.A. (PHM)

Categorie

P/S-ratio voor Pharma Mar, S.A. (PHM)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Pharma Mar, S.A. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Pharma Mar, S.A. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH